Select Bibliography

Filter by any of these (after searching):

Morlan, Bruce W.

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 3 items

Cediranib (AZD2171) in Patients with Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial

Alberts, Steven R. , Fitch, Tom R. , Kim, George P. ... - - Am J Clin Oncol - 2012

Manuscript - Primary - Primary - GI - N044J

Gemcitabine and Doxetaxel for Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial

Alberts, Steven R. , Reid, Joel M. , Morlan, Bruce W. , Farr, Gist H. ... - - Am J Clin Oncol - 2012

Manuscript - Primary - Primary - GI - N0041

Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance)

Xie, Hao , Lafky, Jacqueline M. , Morlan, Bruce W. ... - - Ther Adv Med Oncol - 2020

Manuscript - Primary - Primary - GI - N054C